Hello,

Here's the current outline of the main paper for discussion.

cheers,
Tuuli

Tuuli Lappalainen, PhD
Department of Genetic Medicine and Development
University of Geneva Medical School
CMU / Rue Michel-Servet 1
1211 Geneva 4
Switzerland
Tel. +41-(0)22-3795550
tuuli.lappalainen@unige.ch
On /15/1112 12:35 PM, Michael Sammeth wrote:
Here some update on the splicing companion outline:

Tentative title: 

Splicing Singularities and Population Polymorphisms of Human Transcriptomes


(1) transcriptome composition varies with gene expression

- although gene discovery does not saturate,

   most genes of a certain tissue are expressed ubiquitously across individuals and populations

- population-determinant genes (specific from 1 population) show proliferant factors

   age of cell line bias, pairwise distances and tree

- differentially expressed genes accumulate for cell surface factors


(2) transcriptome configuration changes by differential splicing (DS)

- most genes show little transcript variability

- most variable genes show enrichment for cell surface terms (?), 

   but no significant overlap with DE genes (!)

- alternative psi exons (splicing only)


(3) genetic polymorphisms that influence DS

- fraction of variants in splice site regions, 

  compare to subgenic localization of sQTLs

- classification of splice site variants in 5 distinct groups, characterization:

  activating variants differ in allele frequencies, deteriorating vs. neutral/enhancing indicative of psi exons


(4) discovery of novel elements by RNAseq

- intron variants, number of donors/acceptors...weak are predominantly rare in population

- how many novel events, broken down by type, characterization


Bottom line

- the transcriptomes differ not markedly between individuals/populations

- but quantitative (gene expression level) and qualitative (splicing level) differences occur not (only) at random




On Thu, Nov 15, 2012 at 5:54 AM, Tuuli Lappalainen <Tuuli.Lappalainen@unige.ch> wrote:
Hello all,

We'll have an RNAseq analysis group TC today at 2pm CET. Apologies for the late notice.

I hope many of you can attend since it's been a while due to me traveling; there are a number of important things to discuss:

- updates from Santiago de Chile
- updates from ASHG
- outline, timeline and action items for the main paper
- outlines, timelines and action items for the companion papers
- analysis updates
- AOB

Call details:
Germany         +49 692 573 804 41
Netherlands         +31 108 920 271
Spain         +34 931 816 661
Sweden         +46 840 309 949
Switzerland         +41 58 262 07 22
United Kingdom         +44 203 370 57 19
United States         +1 646 381 08 89
Access code: 611683

best,
Tuuli

-- 
Tuuli Lappalainen, PhD
Department of Genetic Medicine and Development
University of Geneva Medical School
CMU / Rue Michel-Servet 1
1211 Geneva 4
Switzerland
Tel. +41-(0)22-3795550
tuuli.lappalainen@unige.ch

_______________________________________________
Geuvadis_rna_analysis mailing list
Geuvadis_rna_analysis@lists.crg.es
http://davinci.crg.es/mailman/listinfo/geuvadis_rna_analysis




_______________________________________________
Geuvadis_rna_analysis mailing list
Geuvadis_rna_analysis@lists.crg.es
http://davinci.crg.es/mailman/listinfo/geuvadis_rna_analysis